X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) and Lunai Bioworks (NASDAQ:LNAI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Analyst Recommendations
This is a summary of current recommendations and price targets for X4 Pharmaceuticals and Lunai Bioworks, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| X4 Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| Lunai Bioworks | 1 | 0 | 0 | 0 | 1.00 |
X4 Pharmaceuticals presently has a consensus target price of $11.25, suggesting a potential upside of 264.08%. Given X4 Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe X4 Pharmaceuticals is more favorable than Lunai Bioworks.
Insider & Institutional Ownership
Profitability
This table compares X4 Pharmaceuticals and Lunai Bioworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| X4 Pharmaceuticals | -474.74% | -49.62% | -30.80% |
| Lunai Bioworks | N/A | N/A | -42.62% |
Valuation & Earnings
This table compares X4 Pharmaceuticals and Lunai Bioworks”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| X4 Pharmaceuticals | $35.11 million | 8.73 | -$79.20 million | ($0.67) | -4.61 |
| Lunai Bioworks | $51,992.00 | 15.96 | -$3.56 million | ($0.40) | -0.41 |
Lunai Bioworks has lower revenue, but higher earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
X4 Pharmaceuticals has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Lunai Bioworks has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.
Summary
X4 Pharmaceuticals beats Lunai Bioworks on 8 of the 13 factors compared between the two stocks.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body. Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections. X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia.
About Lunai Bioworks
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase.
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
